EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieOpen Access · CC BY-NC 4.0

Twenty percent human albumin solution fluid bolus administration therapy in patients after cardiac surgery-II: a multicentre randomised controlled trial

Geoffrey J Wigmore iD, Adam M Deane iD, Jeffrey J Presneill iD, Glenn Eastwood iD, Ary Serpa Neto iD, Matthew J Maiden iD, Shailesh Bihari iD, Robert A Baker iD, Jayme S Bennetts iD, Rashmi Ghanpur iD, James R Anstey, Jaishankar Raman iD und 2 weitere

Intensive Care Medicine · 2024-07 · 50 (7) · 1075-1085

DOI: 10.1007/s00134-024-07488-3 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Intensive Care Medicine, online erschienen am 02.07.2024. Verfasst von Geoffrey J Wigmore und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Critical Care, Melbourne Medical School, Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Melbourne, VIC, A…. Hauptthemen laut MEDLINE: Fluid Therapy, Cardiac Surgical Procedures, Vasoconstrictor Agents, Crystalloid Solutions. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: CSL Behring, National Health and Medical Research Council, University of Melbourne.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: After cardiac surgery, fluid bolus therapy (FBT) with 20% human albumin may facilitate less fluid and vasopressor administration than FBT with crystalloids. We aimed to determine whether, after cardiac surgery, FBT with 20% albumin reduces the duration of vasopressor therapy compared with crystalloid FBT. METHODS: We conducted a multicentre, parallel-group, open-label, randomised clinical trial in six intensive care units (ICUs) involving cardiac surgery patients deemed to require FBT. We randomised 240 patients to receive up to 400 mL of 20% albumin/day as FBT, followed by 4% albumin for any subsequent FBT on that day, or to crystalloid FBT for at least the first 1000 mL, with use of crystalloid or 4% albumin FBT thereafter. The primary outcome was the cumulative duration of vasopressor therapy. Secondary outcomes included fluid balance. RESULTS: Of 480 randomised patients, 466 provided consent and contributed to the primary outcome (mean age 65 years; median EuroSCORE II 1.4). The cumulative median duration of vasopressor therapy was 7 (interquartile range [IQR] 0-19.6) hours with 20% albumin and 10.8 (IQR 0-22.8) hours with crystalloids (difference - 3.8 h, 95% confidence interval [CI] - 8 to 0.4; P = 0.08). Day one fluid balance was less with 20% albumin FBT (mean difference - 701 mL, 95% CI - 872 to - 530). CONCLUSIONS: In patients after cardiac surgery, when compared to a crystalloid-based FBT, 20% albumin FBT was associated with a reduced positive fluid balance but did not significantly reduce the duration of vasopressor therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Fluid TherapyCardiac Surgical ProceduresVasoconstrictor AgentsCrystalloid SolutionsAlbuminsHumansFemaleMaleAgedMiddle AgedIntensive Care UnitsIsotonic Solutions

Stichwörter der Autor:innen

AlbuminCardiac surgeryCritical careFluid therapyResuscitation

Substanzen

Vasoconstrictor AgentsCrystalloid SolutionsAlbuminsIsotonic Solutions

Autor:innen und Institutionen

  • Department of Critical Care, Melbourne Medical School, Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Melbourne, VIC, Australia. geoff.wigmore@unimelb.edu.au.
  • Department of Anaesthesia and Pain Medicine, Western Health, Melbourne, VIC, Australia. geoff.wigmore@unimelb.edu.au.
  • Department of Critical Care, Melbourne Medical School, Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Melbourne, VIC, Australia.
  • Department of Intensive Care, Royal Melbourne Hospital, Melbourne, VIC, Australia.
  • Australian and New Zealand Intensive Care Research Centre (ANZIC-RC), School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, Australia.
  • Department of Intensive Care, Austin Hospital, Melbourne, VIC, Australia.

ORCID-Profile: Geoffrey J Wigmore, Adam M Deane, Jeffrey J Presneill, Glenn Eastwood, Ary Serpa Neto, Matthew J Maiden, Shailesh Bihari, Robert A Baker, Jayme S Bennetts, Rashmi Ghanpur, Jaishankar Raman, Rinaldo Bellomo

Förderung

  • CSL Behring
  • National Health and Medical Research Council
  • University of Melbourne

Zitieren

APA

Wigmore, G. J., Deane, A. M., Presneill, J. J., Eastwood, G., Serpa Neto, A., Maiden, M. J., Bihari, S., Baker, R. A., Bennetts, J. S., Ghanpur, R., Anstey, J. R., Raman, J., Bellomo, R., & HAS FLAIR-II investigators (2024). Twenty percent human albumin solution fluid bolus administration therapy in patients after cardiac surgery-II: a multicentre randomised controlled trial. Intensive Care Medicine, 50(7), 1075-1085. https://doi.org/10.1007/s00134-024-07488-3

Vancouver

Wigmore GJ, Deane AM, Presneill JJ, Eastwood G, Serpa Neto A, Maiden MJ, et al. Twenty percent human albumin solution fluid bolus administration therapy in patients after cardiac surgery-II: a multicentre randomised controlled trial. Intensive Care Medicine. 2024;50(7):1075-1085. doi:10.1007/s00134-024-07488-3

BibTeX
@article{Wigmore2024,
  author = {Wigmore, Geoffrey J and Deane, Adam M and Presneill, Jeffrey J and Eastwood, Glenn and Serpa Neto, Ary and Maiden, Matthew J and Bihari, Shailesh and Baker, Robert A and Bennetts, Jayme S and Ghanpur, Rashmi and Anstey, James R and Raman, Jaishankar and Bellomo, Rinaldo and HAS FLAIR-II investigators, HAS FLAIR-II investigators},
  title = {Twenty percent human albumin solution fluid bolus administration therapy in patients after cardiac surgery-II: a multicentre randomised controlled trial},
  journal = {Intensive Care Medicine},
  year = {2024},
  volume = {50},
  number = {7},
  pages = {1075--1085},
  doi = {10.1007/s00134-024-07488-3}
}
Kostenlos starten →